Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Tobramycin

FDA-approved product (solution/drops, ophthalmic), marketed as Aktob, Bethkis, Kitabis Pak and 8 more.

Registered studies
50+
Lab records
48
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Tobramycin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Allergic conjunctivitis
  • Bacterial disease
  • Cystic fibrosis
  • Eye infection
  • Infection
  • Inflammation
  • Respiratory tract infectious disorder

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other aminoglycosides; Antibiotics
FDA pharmacologic class
Aminoglycoside Antibacterial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01GB01; WHO ATC S01AA12; FDA class Aminoglycoside Antibacterial

Repurposing investigation

Tobramycin is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA4.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli4.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae51.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis66.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 3 of 10 lab records
  • E. coli: measured active in 6 of 15 lab records
  • K. pneumoniae: measured active in 17 of 23 lab records
Open Tobramycin in ChEMBL Registered studies below
Show the 48 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Tobramycin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Antibiotic Elution in Total Knee Arthroplasty

    NCT03928522 · start 2019-01-28

    Registered record
    Registry ID
    NCT03928522
    Conditions
    Total Knee Replacement
    Interventions
    hand mixed vancomycin; hand mixed tobramycin; pre-mixed tobramycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2019-01-28
    Completion
    2019-09-30
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTotal Knee Replacement
    Interventionhand mixed vancomycin; hand mixed tobramycin; pre-mixed tobramycin
    PhasePhase 4
    Registry statusCompleted

  • Human Factors Study to Validate the User Interface of TOBI Podhaler Using Placebo Capsules

    NCT03502070 · start 2018-06-26

    Registered record
    Registry ID
    NCT03502070
    Conditions
    Cystic Fibrosis
    Interventions
    Placebo; Tobi Podhaler
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2018-06-26
    Completion
    2019-06-17
    Enrolment
    47

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis
    InterventionPlacebo; Tobi Podhaler
    PhasePhase 4
    Registry statusCompleted

  • Evaluation of Short Antibiotic Combination Courses Followed by Aerosols in Cystic Fibrosis

    NCT03066453 · start 2017-06-13

    Registered record
    Registry ID
    NCT03066453
    Conditions
    Cystic Fibrosis
    Interventions
    Tobi Inhalant Product; Nebcin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2017-06-13
    Completion
    2020-01-16
    Enrolment
    23

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis
    InterventionTobi Inhalant Product; Nebcin
    PhasePhase 3
    Registry statusTerminated

  • Tobramycin Delivered by Nebulized Sonic Aerosol for Chronic Rhinosinusitis Treatment of Cystic Fibrosis Patients

    NCT02888730 · start 2017-02-16

    Registered record
    Registry ID
    NCT02888730
    Conditions
    Cystic Fibrosis; Rhinosinusitis; Lung Diseases
    Interventions
    Tobramycin nebulized nasally; Physiologic serum nebulized nasally
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2017-02-16
    Completion
    2019-07-08
    Enrolment
    86

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis; Rhinosinusitis; Lung Diseases
    InterventionTobramycin nebulized nasally; Physiologic serum nebulized nasally
    PhasePhase 3
    Registry statusTerminated

  • Testing the Effect of Adding Chronic Oral Azithromycin to Inhaled Tobramycin in People With Cystic Fibrosis (CF)

    NCT02677701 · start 2016-10-21

    Registered record
    Registry ID
    NCT02677701
    Conditions
    Cystic Fibrosis
    Interventions
    azithromycin; placebo (for azithromycin); inhaled tobramycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-10-21
    Completion
    2020-02-13
    Enrolment
    119

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis
    Interventionazithromycin; placebo (for azithromycin); inhaled tobramycin
    PhasePhase 4
    Registry statusCompleted

  • IV Colistin for Pulmonary Exacerbations: Improving Safety and Efficacy

    NCT02918409 · start 2016-08-26

    Registered record
    Registry ID
    NCT02918409
    Conditions
    Cystic Fibrosis
    Interventions
    Colistin; Tobramycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2016-08-26
    Completion
    2021-11-22
    Enrolment
    51

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis
    InterventionColistin; Tobramycin
    PhasePhase 4
    Registry statusCompleted

  • Locally Applied Antibiotics for Infection Prophylaxis in Treatment of Open Fractures

    NCT03705962 · start 2015-07

    Registered record
    Registry ID
    NCT03705962
    Conditions
    Fractures, Open
    Interventions
    Tobramycin; Placebo: normal saline
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2015-07
    Completion
    2019-03-07
    Enrolment
    11

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFractures, Open
    InterventionTobramycin; Placebo: normal saline
    PhasePhase 3
    Registry statusTerminated

  • Aerosolized Antibiotics in the Treatment of Ventilator Associated Pneumonia

    NCT02478710 · start 2015-06

    Registered record
    Registry ID
    NCT02478710
    Conditions
    Pneumonia, Ventilator-Associated
    Interventions
    Aerosolized Tobramycin or Vancomycin; Aerosolized Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Terminated
    Start
    2015-06
    Completion
    2022-07
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPneumonia, Ventilator-Associated
    InterventionAerosolized Tobramycin or Vancomycin; Aerosolized Placebo
    PhasePhase 4
    Registry statusTerminated

  • Once Daily Aminoglycoside Pharmacokinetics and Optimal Dosing in the Burn Population: A Prospective Study

    NCT02269969 · start 2015-03

    Registered record
    Registry ID
    NCT02269969
    Conditions
    Burns; Infection
    Interventions
    Tobramycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2015-03
    Completion
    2015-12
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBurns; Infection
    InterventionTobramycin
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • Study to Validate the Instructions for Use of TOBI® Podhaler™ in Cystic Fibrosis Patients

    NCT02178540 · start 2014-08

    Registered record
    Registry ID
    NCT02178540
    Conditions
    Cystic Fibrosis
    Interventions
    Placebo; Tobi Podhaler
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-08
    Completion
    2015-02
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis
    InterventionPlacebo; Tobi Podhaler
    PhasePhase 4
    Registry statusCompleted

  • Pharmacokinetic and Pharmacoscintigraphic Comparison of TobrAir® 6.0 With TOBI® and TOBI® Podhaler™

    NCT02207426 · start 2014-07

    Registered record
    Registry ID
    NCT02207426
    Conditions
    Healthy
    Interventions
    Tobramycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-07
    Completion
    2014-09
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionTobramycin
    PhasePhase 1
    Registry statusCompleted

  • OPTIMIZing Treatment for Early Pseudomonas Aeruginosa Infection in Cystic Fibrosis

    NCT02054156 · start 2014-06

    Registered record
    Registry ID
    NCT02054156
    Conditions
    Cystic Fibrosis
    Interventions
    azithromycin; placebo; Tobramycin solution for inhalation
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-06
    Completion
    2018-08-23
    Enrolment
    221

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis
    Interventionazithromycin; placebo; Tobramycin solution for inhalation
    PhasePhase 3
    Registry statusCompleted

  • Cystic Fibrosis Microbiome-determined Antibiotic Therapy Trial in Exacerbations: Results Stratified

    NCT02526004 · start 2013-10-01

    Registered record
    Registry ID
    NCT02526004
    Conditions
    Cystic Fibrosis
    Interventions
    Ceftazidime; Tobramycin
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2013-10-01
    Completion
    2018-06-30
    Enrolment
    223

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis
    InterventionCeftazidime; Tobramycin
    PhaseNot applicable
    Registry statusCompleted

  • Two Trabecular Micro-bypass Stents & Postoperative Travoprost to Treat Glaucoma Subjects on Two Hypotensive Agents

    NCT02873806 · start 2013-03

    Registered record
    Registry ID
    NCT02873806
    Conditions
    Open-angle Glaucoma
    Interventions
    Implantation of two iStent inject micro-bypass stents; Topical travoprost; Two iStent inject micro-bypass stents; Tobramycin; Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2013-03
    Completion
    2019-11-08
    Enrolment
    53

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpen-angle Glaucoma
    InterventionImplantation of two iStent inject micro-bypass stents; Topical travoprost; Two iStent inject micro-bypass stents; Tobramycin +1 more
    PhasePhase 4
    Registry statusCompleted

  • Ext. Long-term Safety Study in CF Patients: Single Arm TIP

    NCT01775137 · start 2013-02

    Registered record
    Registry ID
    NCT01775137
    Conditions
    Long-term Safety of TIP
    Interventions
    TBM100
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2013-02
    Completion
    2014-11
    Enrolment
    45

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLong-term Safety of TIP
    InterventionTBM100
    PhasePhase 4
    Registry statusCompleted